Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Accelerating Clinical Timelines of Induced Pluripotent Stem Cells (iPSCs) with Pluristyx
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
The Challenges and Solutions for Viral Products
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
Opening of Resilience's West Coast Cell Therapy PAD Center
Resilience is proud to announce the official opening of our West Coast (San Diego, CA) Cell Therapy PAD center. This location will serve as our...
Overcoming Obstacles in Gene Therapy Manufacturing
The gene therapy and viral vector space has yet to achieve the level of standardization that typifies established modalities, such as monoclonal...
Resilience Enters Into Strategic Collaboration with Labcorp to Accelerate Cell and Gene Therapies
Resilience has entered into a strategic collaboration with Labcorp to establish a joint customer service offering that provides an end-to-end...
On Demand Webinar: Outsourced Pharma Capacity Update-Large Molecules
Are you an innovator company looking for a reliable and innovative partner? You have come to the right place.
